Label: DEXTROSE- dextrose monohydrate injection, solution

NOTE: This solution is hypertonic - See WARNINGS and PRECAUTIONS.

LifeShield® Abboject® Syringe

Abboject® Syringe

Fliptop Container

Ansyr® II Plastic Syringe
Rx only

50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for injection for intravenous injection as a fluid and nutrient replenisher.

Each mL of fluid contains 0.5 g dextrose, hydrous which delivers 3.4 kcal/gram. The solution has an osmolarity of 2.53 mOsmol/mL (calc.), pH 3.2 to 6.5 and may contain sodium hydroxide and/or hydrochloric acid for pH adjustment.

The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit.

Dextrose, USP is chemically designated C6H12O6 ∙ H2O (D-glucose monohydrate), a hexose sugar freely soluble in water.

Dextrose, hydrous has the following structural formula:

Water for Injection, USP is chemically designated H2O.

The syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

When administered intravenously this solution restores blood glucose levels in hypoglycemia and provides a source of carbohydrate calories.

Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injection undergoes oxidation to carbon dioxide and water.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels.

The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and avoid production of hyperglycemia.

A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated.

Dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

50% Dextrose Injection is hypertonic and may cause phlebitis and thrombosis at the site of injection.

Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.

The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

Additives may be incompatible. Consult with pharmacist if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Do not use unless the solution is clear and seal is intact. Discard unused portion.

Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Blood electrolyte monitoring is essential and fluid and electrolyte imbalances should be corrected. Essential vitamins and minerals also should be provided as needed.

To minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and if necessary, add insulin.

When a concentrated dextrose infusion is abruptly withdrawn, it is advisable to follow with the administration of 5% or 10% dextrose injection to avoid rebound hypoglycemia.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Care should be exercised to ensure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis should occur during administration, the injection should be stopped and corrective measures instituted.

Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.

Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS.

50% Dextrose Injection, USP is supplied in single-dose containers as follows:

Abboject® is a trademark of Abbott Laboratories.

LifeShield® is the trademark of ICU Medical, Inc. and is used under license.

For Medical Information about 50% Dextrose Injection, please visit www.pfizermedinfo.com or call 1‑800-438-1985.

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

LAB-1027-7.0

Revised: July 2024

50% DEXTROSE

50 mL Single-dose
Rx only
NDC 0409-7517-66

50% DEXTROSE Injection, USP
25 g/50 mL (0.5 g/mL)

For intravenous use. Usual dosage: See insert. Sterile, nonpyrogenic.
2.53 mOsmol/mL (calc.). pH 4.2 (3.2 to 6.5)

Distributed by
Hospira, Inc., Lake Forest, IL 60045 USA
Hospira
RL-7117

LOT ##-###-AA
EXP DMMMYYYY

50 mL
NDC 0409-7517-66

50%
DEXTROSE
Injection, USP

25 g/50 mL (0.5 g/mL)

Ansyr®II

Unit of Use Syringe

Rx only

LOT #####AA
EXP DMMMYYYY

Hospira

◀ PRESS AND PULL TO OPEN ▶

50% DEXTROSE

50 mL Single-dose
Rx only
NDC 0409-4902-64

50% DEXTROSE Inj., USP
25 g/50 mL (0.5 g/mL)

For intravenous use. Usual dosage: See insert.
Sterile, nonpyrogenic. 2.53 mOsmol/mL (calc.) pH 4.2 (3.2 to 6.5)
Distributed by
Hospira, Inc., Lake Forest, IL 60045 USA

Hospira

RL–7116

LOT ##–###–AA

EXP DMMMYYYY

50 mL
NDC 0409-4902-64

50%
DEXTROSE
Injection, USP

25 g/50 mL
(0.5 g/mL)

LIFESHIELD®

Glass
ABBOJECT®
Unit of Use Syringe

with male luer lock
adapter and
18-Gauge protected needle

Rx only

Hospira

LOT #####AA

EXP DMMMYYYY

◀ PRESS AND PULL TO OPEN

50 mL Single-dose

50% Dextrose
Injection, USP

25 grams/50 mL
(0.5 g/mL)
Contains no more than 600 mcg/L of
aluminum.
Distributed by Hospira, Inc.
Lake Forest, IL 60045 USA

Hospira

50 mL Single-dose Fliptop Vial

Rx only
NDC 0409-6648-02
Contains 25 of NDC 0409-6648-16

50% Dextrose Injection, USP

25 grams/50 mL
(0.5 g/mL)

Hospira

50 mL Single-Dose Syringe

Rx only

NDC 0409-0505-15

50% DEXTROSE Inj., USP
25 g/50 mL (0.5 g/mL)

For intravenous use. Recommended Dosage: See Prescribing
Information.
Sterile, nonpyrogenic. 2.53 mOsmol/mL (calc.) pH 3.2 to 6.5

Distributed by Hospira, Inc.,
Lake Forest, IL 60045 USA

Hospira

PRESS AND PULL TO OPEN

50 mL

NDC 0409-0505-15

Rx only

50%
DEXTROSE
Injection, USP

25 g/50 mL
(0.5 g/mL)

For intravenous use

with male luer lock adapter

Glass
Abboject®
Single-Dose Syringe

Hospira